Advertisement

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Victoria T. Brown, PharmD, BCOP, on Payer Intervention: The Example of Abiraterone

Focus on Optimized Dosing of Ibrutinib Panel Discussion

R. Donald Harvey, PharmD, BCOP, FCCP, FHOPA, on Alternative Dispensing Strategies

Advertisement

Advertisement




Jul
02
Today In Oncology
Study Reveals Long-Term Consequences of Chemotherapy on Healthy Blood Cells
Lean Body Mass–Based Oxaliplatin Dosing and Risk of Neurotoxicity in Adjuvant Treatment of Stage III Colon Cancer
Can Hormone Therapy Affect Breast Cancer Risk in Younger Women
Uterine Cancer Incidence and Mortality Rates Projected to Rise Substantially by 2050
Metastatic Castration-Resistant Prostate Cancer Comparison of Second-Line Regimens
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo